Home-based care has become a precision M&A market. With margins compressed and capital concentrated, data discipline is the variable separating similar businesses into very different multiples. A thought piece on what changed in diligence, what buyers actually pay for, and how operators move from data to performance to value.
Goal
To examine how data and technology have moved from peripheral diligence items to the central variable that determines valuation in home-based care M&A, and to walk through the practical implications for founders, operators, and ownership groups.
Key Takeaways
- Home-based care is a precision M&A market. Roughly 51,000 agencies, roughly 120 transactions per year. In a constrained-margin environment, data and technology are what separate businesses with similar revenue and service mix into very different multiples.
- Buyers no longer evaluate tools or dashboards. They evaluate how consistently data shows up in decisions, workflows, and outcomes.
- AI and data have moved from appendix material to a top diligence question because they now serve as proxies for execution risk and post-close scalability.
- Deals are increasingly lost in integration, not in negotiation. Weak data foundations extend J-curves and suppress realized value.
- Sellers who can demonstrate how performance is actually produced command premium multiples. Sellers who cannot are priced on potential, and potential is being discounted.
- Valuation today is a lagging indicator of operational truth.
What This Article Covers
- The shift: from appendix material to top diligence question
- Home-based care as a precision M&A market
- Why deals don’t close anymore
- What buyers actually pay for
- From data to performance: the operating reality
- The diligence reality that wasn’t there five years ago
- What this means for operators
- About Montauk AI
- FAQ
The Shift: From Appendix Material to Top Diligence Question
Five years ago, the technology and data section of a home-based care diligence package was an appendix item. Buyers wanted to know what EHR was in place, what billing system was running, and whether basic operational reporting was functional. The answers rarely moved valuation. The narrative around the deal was built on EBITDA, growth, payer mix, and clinical quality.
That has changed.
Today, the data and technology questions sit at or near the top of the diligence list, sometimes ahead of EBITDA decomposition. Margins in home-based care have compressed across the cycle. Workforce constraints have pushed organic growth assumptions down. Public buyers and sponsor-backed platforms are now underwriting integration risk and post-close performance more aggressively than they were when capital was cheaper and margins more forgiving.
In that environment, the data and operating discipline of the seller has become a proxy for the two things buyers care most about: execution risk and post-close scalability. A buyer looking at two similar agencies, with similar revenue and similar service mix, increasingly differentiates them on which one has built operating discipline around data and which one has not. The multiple math follows.
This is not a small shift. It is the most consequential change in how home-based care assets are underwritten this decade.
Home-Based Care as a Precision M&A Market
A useful frame for what is happening: home-based care M&A is not a volume market. It is a precision market.
The numbers tell the story. Roughly 51,000 House Based Care Providers. Consisting of 33,000 home care provides, 11,500 Medicare-certified HHAs. 6,500 Medicare-certified hospices operate in the segment. Roughly 105 transactions clear per year. That is a tiny fraction of the operator base transacting in any given window, against a buyer universe holding more capital than viable assets to deploy it on.
In a precision market, every variable that distinguishes one asset from another matters. Margin profile, payer mix, branch-level performance, growth trajectory, and now, increasingly, the data discipline that produces those results. The room for “similar to the comp, with a footnote” pricing is small. The buyer either understands what is producing the financial profile in front of them, or they discount for the uncertainty.
For sellers, this means the underwriting work that buyers do on the asset has gotten substantially more sophisticated, and the seller’s preparation has to match. A trailing twelve months of strong EBITDA without a coherent story for how that performance is produced and how it will scale post-close is no longer enough. Buyers want both numbers and proof of the engine that generates them.
Why Deals Don’t Close Anymore
Among letters of intent signed in home-based care, a substantial share never reach close. The failure mode that has grown most prominently is integration risk surfaced during diligence.
Buyers, particularly public and sponsor-backed platforms, are now intensely focused on speed-to-integration and limiting the J-curve post-close. Every additional month of integration friction is a month of underperformance against the underwriting model. Every gap in data infrastructure that has to be reconciled or rebuilt after close compounds that friction.
Weak data foundations are the most common source of this. When financial data does not roll up cleanly from branch to corporate, when operating reports require manual reconciliation, when clinical quality and staffing data live in disconnected systems, the buyer’s integration team is signing up for a six-to-twelve-month catch-up project that was not visible at the LOI.
The deal either retrades on the discovery, gets restructured to push risk back to the seller through earnouts and holdbacks, or breaks. What buyers see in your data room surfaces these gaps before negotiation, not after.
Cultural resistance to data discipline is the version of this that is hardest to see. An agency where the leadership team treats reports as compliance documents rather than operating instruments will look fine on paper and feel wrong in management presentations.
Buyers who have integrated enough acquisitions can recognize this within a meeting, and the price they offer reflects it.
The practical implication is direct. Sellers who can demonstrate, with evidence, how quickly performance will stabilize after close, and what infrastructure makes that possible, get cleaner deals and higher prices. Sellers who cannot are pricing on potential, and potential is being discounted heavily.
What Buyers Actually Pay For
The most consistent observation in conversations with strategic and sponsor-backed buyers in home-based care today: they are not paying for tools.
A dashboard does not move valuation. A new EHR install does not move valuation. A consultant’s recommendation memo does not move valuation.
What moves valuation is the evidence that data and technology are changing how the business is actually run, that decisions are being made consistently against that data, and that the performance result is repeatable.
This shows up across three dimensions.
Data Maturity Changes Risk Perception
A buyer evaluating an asset where branch-level KPIs are clean, monthly close is tight, and operational reporting has been stable for thirty-six months underwrites less risk than the same financial profile produced by an organization with cash-basis accounting and manual workflows.
Less risk translates directly into a different multiple. Quality of earnings readiness is the financial expression of this.
Flexibility Shows Up in the Diligence Narrative
Sellers with infrastructure that allows them to model scenarios, stress-test cost structure, and adjust to regulatory changes — such as staffing minimums, reimbursement changes, or compliance audits — present buyers with an asset that is structurally easier to integrate and grow.
Buyers pay for that flexibility, even when the seller is not explicitly selling it.
The Narrative of How Performance Is Produced
Two agencies with identical TTM revenue and EBITDA can present radically different stories about how those numbers came together.
The seller who can show the data discipline, operating system, and execution rigor that produced the result commands a premium. The seller who cannot is selling a snapshot, and snapshots get priced conservatively.
From Data to Performance: The Operating Reality
The shorthand we use with operators we work with: data matters when it changes behavior.
Reports that sit in inboxes do not create value. Data that drives weekly operating decisions, that informs staffing and scheduling, that surfaces issues before they reach the P&L, is what produces the performance buyers underwrite.
The best operators in home-based care are not just collecting data. They are building data infrastructure that allows them to do three things.
Move Faster
When a state changes reimbursement rules or staffing requirements, the operator who has connected operating data can model the impact and respond within weeks.
The operator without that infrastructure absorbs the change as friction.
Repurpose, Not Just Cut
Cost discipline is table stakes. The operators who win in this market use data to identify where to redeploy capacity, not just where to remove it.
Workforce utilization, route density, scheduling efficiency, and clinical productivity all become levers when the data infrastructure supports them.
Our operating leverage playbook for home-based care walks through these levers in detail.
Pursue More Sophisticated Acquisitions
Operators with strong data infrastructure can underwrite, integrate, and improve acquired agencies faster than competitors.
They become preferred consolidators, get first look at quality assets, and pay rational prices because they have confidence in the post-close trajectory.
This is what “almost-predictive” operating capability looks like. The point is not full automation. The point is that data discipline has compounded into operational adaptability, and adaptability has become the strategic advantage in a constrained market.
The Diligence Reality That Wasn’t There Five Years Ago
Look at home-based care diligence packages from five years ago. The technology section was a paragraph and a list of systems.
Today the same section is a substantial portion of the diligence, with questions about data architecture, reporting cadence, integration capability, decision discipline, and how technology investment ties to actual operating outcomes.
Buyers are not asking these questions because technology is interesting. They are asking because the answers have become predictive of post-close performance in ways that other diligence variables are not.
This creates new categories of risk for sellers who are not prepared, and new categories of opportunity for sellers who are.
The asymmetry is sharp. An operator who has built data discipline over the last three years walks into a process with a story buyers are actively looking for. An operator who has not is selling against the same expectation without the evidence to meet it.
Valuation today is a lagging indicator of operational truth.
What This Means for Operators
For founders and ownership groups operating in home health, hospice, home care, palliative, or post-acute care, the practical takeaways are direct.
If a Sale Is on the Horizon
If a sale is on the horizon in the next twelve to twenty-four months, the data infrastructure investment that makes a difference at the transaction is the investment made now, not the investment made during the process.
Buyer diligence has gotten too sophisticated to retrofit narrative. Our 12-month seller readiness plan walks through the timeline operators should hold themselves to.
If a Sale Is Further Out
If a sale is further out, the same investment compounds.
The operator who builds data discipline today will have eighteen, thirty-six, or sixty months of operating evidence by the time they choose to transact. That evidence is what produces premium multiples.
If a Sale Isn’t on the Horizon
If a sale is not on the horizon at all, the work still matters.
Operators with strong data infrastructure outperform peers organically, weather regulatory changes more gracefully, and have optionality their competitors lack.
The discipline that makes an asset valuable to a buyer is the same discipline that makes a business more durable.
The question every operator should be asking is the one we put to our clients: are you building performance, or are you accumulating technology?
About Montauk AI
Montauk AI is a home-based care investment bank. We work with founder-led and mid-market operators across home health, hospice, home care, palliative, and post-acute care, across the full Operate, Optimize, Exit lifecycle.
In Operate, we build the FP&A foundation, KPI infrastructure, monthly close cadence, and board-ready reporting that defines a serious business.
In Optimize, we engineer enterprise value through EBITDA uplift, workforce utilization, clinical and star-rating improvements, payer optimization, and technology enablement.
In Exit, we run the transaction itself through algorithmic buyer matching, CIM and comps strategy, and AI-accelerated execution.
Some of these themes will be discussed live at Home Care 100, Summer 2026, in a panel titled Data to Value(ation): Capitalizing on Your Tech Stack, moderated by Jarrett Bauer with Jon Fradin (CFO, HouseWorks), Dave Marchand (CIO, New Day Healthcare), and Brian Mills (SVP Growth, The Pennant Group).
For our extended treatment of the architecture behind this work, see our AI-Native Investment Banking research paper.
Considering an Exit in the Next Twelve to Twenty-Four Months?
The readiness work begins now.
If you operate in home health, hospice, home care, palliative, or post-acute and are thinking about what the next decade looks like for your business, we would welcome the conversation.
Reach Jarrett Bauer at jbauer@montauk.ai, or learn how we engage across Operate, Optimize, Exit at montaukai.com.
FAQ
Why has data become such a focus in home-based care M&A diligence?
Margins have compressed, workforce constraints have made organic growth harder to underwrite, and buyers are pricing post-close performance more aggressively.
In that environment, data discipline has become a proxy for two things buyers care most about: execution risk and post-close scalability.
Two agencies with similar financials but different data discipline are now underwritten differently, and the multiple math reflects that.
What are buyers actually looking for in the data and technology section of diligence?
Not tools. Evidence.
Specifically: branch-level KPIs that have been clean for thirty-six months or more, financial data that rolls up cleanly without manual reconciliation, operating reports that are used in weekly decisions rather than filed as compliance documents, and a coherent narrative showing how technology investment translates into operating outcomes.
The question buyers are asking is whether the performance they see in the financials will continue after close.
How does data maturity affect home-based care valuation multiples?
Data maturity changes risk perception, which changes the multiple math directly.
A buyer evaluating an asset with strong data discipline assumes a faster, cleaner integration and more predictable post-close performance.
That assumption translates into a lower risk premium and a higher multiple.
The same financial profile produced by an operator without that discipline gets discounted for integration risk.
What does “data that changes behavior” actually mean?
Data infrastructure earns its keep when it moves weekly operating decisions.
Staffing, scheduling, clinical productivity, route density, payer optimization, workforce utilization. Reports that sit in inboxes do not create value.
Reports that surface issues before they reach the P&L, and that inform what an operator does on Monday morning, do.
The distinction matters at diligence because buyers can tell which kind of organization they are evaluating within a single management meeting.
When should an operator start investing in data infrastructure if a sale is contemplated?
Earlier than most operators expect.
The data infrastructure investment that moves the needle at transaction is the investment made twelve to twenty-four months before going to market, not the investment made during the process.
Buyer diligence has become too sophisticated to retrofit narrative.
Operators preparing for a sale eighteen months out have the time to let data discipline show up in the trailing twelve months that buyers will price.
Is there a difference in how strategic and PE buyers evaluate data and technology?
Some, but less than there used to be.
Strategic acquirers focus on integration capability and whether data architecture will plug into theirs.
Financial sponsors focus on operating evidence and whether the platform can absorb additional acquisitions.
Both are now treating data discipline as predictive of post-close performance.
Both discount sellers who cannot demonstrate it.
What is the J-curve in home-based care M&A, and why do buyers focus on it?
The J-curve is the typical pattern where performance dips temporarily after close, driven by integration friction, system transitions, and the time it takes for the buyer’s operating model to be applied to the acquired asset.
Every additional month of friction is a month of underperformance against the underwriting model.
Strong data foundations compress the J-curve. Weak data foundations extend it, sometimes by quarters.
The depth and duration of that curve increasingly determines whether an acquisition produces the returns the buyer underwrote.
